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Organ Printing: a novel tissue engineering paradigm
The number of medical devices implanted in human bodies is surging.
Nearly half a million coronary stents - metal gadgets to hold arteries open -
are installed in human chests each year in the United States. There are
325,000 knee replacements every year, 165,000 artificial hips, 177,000 cardiac
Today: 
pacemakers and 2.5 million eye lenses after cataract surgery. About 46,000
people a year get internal cardiac defibrillators to treat excessive heart rate.
78,000 kidney
4,000 heart
19,000 liver
450,000 cardiac bypass surgery (arteries)
Demand for replacement organs 
Today (in the USA alone): 
100,000 leg arteries bypass
350,000 dialysis access 
A number of those on the waiting list die before a solution can be found. If no 
remedy to these problems is soon found, the situation will become critical in the 
not so distant future (in your lifetime).
Source for replacement organs 
Matching donors
Cadavers
Xenotransplantation
Artificial organs 
Today: 
Tissue engineering-
Regenerative medicine 
Glimpse into what is coming
The Tomorrow: building organs by printing 
Rapid prototyping biofabrication methods
Bioprinting
The bioink
The biopaper
The bioprinter
Organ Printing Technology Developed at MU, licenced to Organovo, Inc.
Spherical or cylindrical cell 
aggregate: the bioink
Supporting biocompatible gel: the 
biopaper
Organ Printing Technology Developed at MU, licenced to Organovo, Inc.
(Scaffoldless technology, based on developmental principles; fusion, cell sorting)
Novogen Printer
After Printing, Blood Vessels Are Matured in Bioreactors
Branching tubes
Other graft products
Nerve grafts
Functional Myocardial Graft
Vascular Health Presents Several Sets Of Large And Growing 
Opportunities For Medical Innovation
Dialysis 
access
Leg Artery Grafts
100,000 leg bypass
surgeries year currently
100,000 new patients/year
350,000 total patients
$1.1B
$1.0B
$1.3B
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Projections
Cardiac 
bypass
450,000 cardiac bypass
surgeries year currently
>$3B Global Opportunity
Organovo’s Bioprinter Technology Now Ready for Wide Use
Organovo Bioprinter Sales Can Be Driven by Key Opinion Leader Sites
12
Key technology/clinical partner
Proposed bioprinting center
Organovo Has Used The Past 12 Months and Initial Seed Funding
to Make Major Strides
• Moved operations forward – opened site in San Diego, tech transfer 
from University of Missouri (10 employees)
• Advanced the science – New NIH grant September 1, animal studies 
by U. Missouri, blood vessel proof of concept trial design w/U. 
Wisconsin, primary human cells in use
• Printer development project – first new top of the line printers 
• Confirmed the market – Quantitative and 
qualitative market research that gives high 
confidence in the business plan
• Created new markets – Bioprinter market 
plans are being executed
delivered and ready for wide research use
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